Zevra Therapeutics, Inc.
Key Metrics
- Previous Close
- $12.13
- 52-Week Range
- $7.16 – $15.04
- Market Cap
- $706.07M
- P/E (TTM)
- 12.13
- EPS (TTM)
- 0.98
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 3.42
- PEG Ratio
- 10.67
- Return on Equity
- 34.80%
- Return on Assets
- 8.74%
- Gross Margin
- 95.46%
- Operating Margin
- 42.30%
- Profit Margin
- 42.82%
- Current Ratio
- 5.17
- Debt/Equity
- 0.01
- Total Debt
- $1.50M
- Free Cash Flow
- $48.38M
- Revenue Growth
- 53.30%
- Earnings Growth
- -88.40%
- Enterprise Value
- $486.00M
Market Snapshot
About
Zevra Therapeutics is a rare disease company developing therapies for patients with limited treatment options. The company focuses on central nervous system disorders and other rare conditions through both proprietary and licensed product candidates. Zevra combines clinical development expertise with specialized commercialization capabilities to serve underserved patient populations.